BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-358 Ind Application With No Objection

- Cloudbreak Pharma Inc 2592.HK:

  • FDA COMPLETES SAFETY REVIEW OF CBT-358 IND APPLICATION WITH NO OBJECTION


Further company coverage: 2592.HK